Leerink Partners raises EnGene Therapeutics to outperform from market perform; raises target price to $5
ENGN•Leerink Partners raised its rating on EnGene Therapeutics to outperform from market perform and raised its target price to $5.
ENGN•ENGN•ENGN•Leerink Partners raised its rating on EnGene Therapeutics to outperform from market perform and raised its target price to $5.
